Galapagos released topline data from two phase 3-enabling studies of its oral, selective TYK2 inhibitor GLPG3667. In dermatomyositis, the Galarisso study met its primary endpoint at week 24, with GLPG3667 150 mg once daily plus standard of care showing a statistically significant benefit on the Total Improvement Score versus placebo in a small cohort (n=21 vs n=19) using a pre-specified alpha of 0.1 (p=0.0848; delta 14.26). Multiple secondary measures, including TIS20/40/60 and mCDASI-A, moved in the right direction. In systemic lupus erythematosus, the Galacela study did not meet its primary endpoint of dose response on SRI-4 at week 32, though numerical gains favored GLPG3667 on several secondary, particularly skin-related, endpoints. Safety was consistent with prior experience. Galapagos is evaluating strategic options, including resuming partnering, aided by a waiver from Gilead under their long-standing collaboration to facilitate external deals. Final 48-week SLE data are expected in the second quarter of 2026.
The split outcome reframes GLPG3667 from a broad systemic autoimmune bet into a targeted rare-disease opportunity with optionality in dermatology-dominant phenotypes. The dermatomyositis signal, while based on a small sample and a less conventional statistical threshold, is clinically relevant in a setting with only one approved therapy and substantial steroid burden. Conversely, the SLE miss highlights the persistent challenge of composite endpoints and disease heterogeneity, and suggests TYK2’s strength may align more with skin and musculoskeletal domains than multiorgan control.
For Commercial teams, this matters now because dermatomyositis represents a concentrated, specialist-driven market where an oral agent with a clean safety profile could command premium pricing and rapid uptake, provided functional outcomes and steroid-sparing effects are demonstrated in larger trials. Payers will look for robust, reproducible gains on validated measures like TIS and mCDASI-A, health status improvements, and real-world reductions in IVIG utilization and corticosteroid exposure. For Medical Affairs, the imperative will be education on TIS interpretation, harmonization of endpoints across registrational studies, and generation of RWE to support economic and quality-of-life claims in a rare population treated across rheumatology, neurology, and dermatology.
Competitive dynamics in TYK2 are shifting. Deucravacitinib, an allosteric TYK2 inhibitor, set the class benchmark in psoriasis and continues to probe additional indications; Takeda’s TAK-279 (acquired from Nimbus) has signaled strong dermatology potential. GLPG3667, an ATP-competitive kinase domain inhibitor, will be evaluated by regulators and payers through a different lens, particularly on selectivity and any perceived proximity to the JAK class. If its tolerability remains favorable, differentiation may hinge less on mechanism and more on indication strategy, trial design, and the ability to win in rare autoimmune niches where endpoint alignment and clinician engagement can accelerate adoption.
With Gilead’s waiver unlocking optionality, partnering is the fulcrum. A well-capitalized immunology player seeking a rare-disease foothold could underwrite a rapid, risk-managed registrational program in dermatomyositis, potentially expanding into cutaneous lupus subsets if the skin signal holds. The strategic question is whether Galapagos can convert a proof-of-concept built on alpha 0.1 into a Phase 3 package that satisfies regulators and persuades payers before 48-week SLE data reset expectations. The next move—partner selection, trial architecture, and choice of endpoints—will determine whether GLPG3667 becomes a focused leader in myositis and related dermatoses or remains a promising class experiment constrained by the realities of SLE.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
